Abstract Recently, we have shown that the new G-protein-coupled estrogen receptor GPR30 plays an important role in the development of tamoxifen resistance in vitro. This study was undertaken to evaluate the correlation between GPR30 and tamoxifen resistance in breast cancer patients. GPR30 protein expression was evaluated by immunohistochemical analysis in 323 patients with primary operable breast cancer. The association between GPR30 expression and tamoxifen resistance was confirmed in a second cohort of 103 patients treated only with tamoxifen. Additionally, we evaluated GPR30 expression in 33 primary tumors and in recurrent tumors from the same patients. GPR30 expression was detected in 56.7% of the breast cancer specimens investigated and it correlated with overexpression of HER-2 (P = 0.021), EGFR (P = 0.024) and lymph node status (P = 0.047). In a first cohort, survival analysis showed that GPR30 was negatively correlated with relapse-free survival (RFS) only in patients treated with tamoxifen (tamoxifen with or without chemotherapy). GPR30 expression was associated with shorter RFS (HR = 1.768; 95% CI, 1.156-2.703; P = 0.009). In a subset of patients treated only with tamoxifen, multivariate analysis revealed that GPR30 expression is an independent unfavorable factor for RFS (HR = 4.440; 95% CI, 1.408-13.997; P = 0.011). In contrast, GPR30 tended to be a favorable factor regarding RFS in patients who did not receive tamoxifen. In 33 paired biopsies obtained before and after adjuvant therapy, GPR30 expression significantly increased only under tamoxifen treatment (P = 0.001). GPR30 expression in breast cancer independently predicts a poor RFS in patients treated with tamoxifen.
Introduction
Tamoxifen is the most frequently used anti-hormonal drug for treatment of women with hormone-dependent breast cancer. Tamoxifen treatment is very effective in tumors expressing estrogen receptors (ER) and significantly reduces the mortality of breast cancer patients [1, 2] . Many patients with ER-positive breast cancer benefit from antihormonal treatment, but unfortunately, almost all patients eventually acquire resistance to these drugs. Several mechanisms underlying tamoxifen resistance have been proposed [3] . The lack of response or acquired resistance to antihormonal drugs remains a major clinical issue.
Recently, we have found that G-protein-coupled receptor GPR30 plays an important role in the development of tamoxifen resistance in breast cancer MCF-7 cell line [4] . GPR30 has been claimed to be a new membrane-bound estrogen receptor involved in the rapid nongenomic effects of estrogen [5] . It has been demonstrated that GPR30 mediates the proliferative effects of estrogen in breast cancer cells, endometrial cancer cells, and ovarian cancer cells [6] . Moreover, ER antagonists such as tamoxifen and fulvestrant act as agonists for GPR30 and stimulate cell proliferation and growth [6] [7] [8] [9] [10] [11] . Long-term tamoxifen treatment of MCF-7 cells increased the E2-stimulated up-regulation of GPR30 and its translocation from endoplasmic reticulum to the cell surface [4] . GPR30 converts tamoxifen to a growth stimulator because its ability to act as an agonist for GPR30. In our experiments, EGFR transactivation via GPR30 was an important mechanism by which MCF-7 cells developed resistance to endocrine therapy [4] . It has been shown that crosstalk between steroid receptors and growth factor receptor pathways plays a key role in the development of resistance to endocrine therapy in breast cancer [12] .
To verify these findings in breast cancer patients, we investigated the expression of GPR30 and EGFR in breast cancer tissue and compared it to established clinicopathological parameters and clinical outcome in terms of relapse-free survival (RFS) and overall survival (OS). To investigate the expression of GPR30 during breast cancer progression, we compare it in 33 primary tumors and in their corresponding relapsed or metastasized tissues.
Materials and methods

Immunohistochemistry
GPR30 expression was analyzed as previously described [13] . Sections of formalin-fixed and paraffin-embedded breast cancer specimens or corresponding recurrent lesions (3.0 lm thick) were mounted on SuperFrost Plus glass slides (Menzel, Braunschweig, Germany) and dried overnight. A Benchmark XT (Ventana, Unterhaching, Germany) conducted the immunostaining. The slides were incubated with affinity-purified rabbit antibody against GPR30 (SP4677P; Acris antibodies, Herford, Germany) diluted 1:500 and against EGFR (Dako, Hamburg, Germany) diluted 1:500 for 32 min at 37°C, after antigen retrieval with Protease I (Ventana) for 10 min. The reactions were visualized by DAB detection. The slides were counterstained with hematoxylin and cover slipped after being embedded in mounting medium.
Evaluation of GPR30 staining results GPR30 expression was classified as already described [13] , according to the following grading system: staining extensity was categorized as 0 (no positive cells), 1 (\10% positive cells), 2 (10-50% positive cells), or 3 ([50% positive cells), and staining intensity was categorized as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). The individual categories were multiplied to give a total immunohistochemical score (IHC). IHC score ranged between 0 and 9. The GPR30 cut-off was determined using the GPR30 expression in normal breast tissue surrounding the invasive breast cancer and is in agreement with the fact that cancer-associated fibroblasts show a robust functional GPR30 response [8] . GPR30-positive expression was defined for tumors that showed an IHC C 3. Representative examples of different GPR30 expression are shown in Fig. 1 . The specificity of the GPR30 peptide antibody was tested in cell lysates prepared from human embryonic kidney HEK-293 cells, human breast cancer MDA-MB231 and MCF-7 cells (Supplementary Fig. 1 ). GPR30 antibody detected a band with an estimated molecular weight of 42 kDa only in MCF-7 cells. In HEK-293 and MDA-MB231 who do not express GPR30 [7, 14, 15] there was no detectable band. The transfection of MCF-7 cells with GPR30 anti-sense oligonucleotides as already described [4] , reduced the expression of GPR30 significantly, resulting in a reduced intensity of the detected specific band ( Supplementary Fig. 1 ). These data suggest that GPR30 antibody specifically detect the GPR30 protein.
Evaluation of EGFR expression
EGFR expression was determined as already described [16] . For assessment of EGFR expression, a following scoring system was used: (0) no staining or unspecific staining; (1) weak and incomplete expression of more than 10% of the tumor cells; (2) moderate and complete staining of more than 10% and (3) strong and complete staining of more than 10% of the cells. The staining was complete in a case of circumferential staining of the entire cell surface. The opposite was considered as incomplete. Representative examples of EGFR expression are shown in Fig. 1f -h.
Patients and tissue samples
The data of 384 patients with primary invasive breast cancer, who had been admitted to the Department of Obstetrics and Gynecology, Otto-von-Guericke University, Magdeburg, Germany from 1999 to 2005, were selected by retrospective analysis. Exclusion criteria included a previous history of adjuvant anti-hormonal or cytostatic therapy, primary non-operable tumor, no available archive material for detection of GPR30 expression and incomplete followup data. Three hundred twenty-three patients were eligible for analysis. There was no significant difference between the final data set of 323 patients and the original group of 384 patients in terms of the patient and tumor characteristics. Patients underwent either modified radical mastectomy (n = 175, 54.2%) or breast conservation surgery (n = 148, 45.8%) in combination with axillary lymph node dissection. Adjuvant chemotherapy was given to 159 (49.2%) patients mainly cyclophosphamide/methotrexate/ 5-fluoruracil (CMF) or epirubicin/cyclophosphamide (EC). Two hundred sixty-eight (82.9%) patients received adjuvant hormonal therapy. The median age at the time of primary diagnosis was 63 years (range 29-97 years), with 69 (21.4%) premenopausal and 254 (78.6%) postmenopausal. Outcome was measured as RFS and overall survival (OS), according to the International Union Against Cancer (IUCC) criteria [17] . The follow-up was performed at the first recurrence of disease, patient death, or was based on the last available data in patient's registry. The median follow-up time of the study population was 51 months (range 1-134 months).
For validation of the results in the first cohort, we used a second cohort including 103 patients treated only with tamoxifen after surgery. The median age at the time of primary diagnosis for the second cohort was 67 years (range 37-97 years), 15 (14.6%) of whom were premenopausal and 88 (85.4%) were postmenopausal. The median follow-up time of the study population was 51 months (range 2-118 months).
The main prognostic factors assessed in this study were patient age, menopausal status, estrogen receptor (ER), progesterone receptor (PR), HER-2 status, tumor size, tumor grading, histological type, and lymph node status. The tumors had been previously characterized immunocytochemically for their ER, PR, and HER-2 status. Histological grade had also been assessed at the time of diagnosis from hematoxylin/eosin sections. The patient's characteristics are summarized in Table 1 .
Statistical analysis
The statistical calculations were performed using SPSS Version 17.0 (SPSS, Chicago, IL, USA). An association between GPR30 expression and the tumor variables was evaluated using the x 2 test or Fisher's exact test. RFS and the OS were chosen as endpoints in this study. RFS analysis took into account those who died of breast cancer-specific death or had a recurrence of disease as a primary event. Patients who died of other causes or patients lacking follow-up data were censored. Survival was calculated using the KaplanMeier method. The equality of survival curves was tested by the log rank test. Univariate Cox proportional hazard regression analysis was used to identify significant prognostic factors. The prognostic significance was evaluated by multivariate analysis. The statistical analyses were two sided and P values of \0.05 were considered statistically significant. The expression of GPR30 in primary tumors (PT's) and their corresponding recurrent lesions was analyzed using nonparametric paired analysis, and was performed with the Wilcoxon signed rank sum test.
Results
GPR30 and EGFR protein expression
According to the inclusion criteria, from the 384 patients obtained from our database, 323 patients were eligible for analysis. Patients were considered positive for GPR30 if they had an IHC score of at least 2. GPR30 expression was observed predominantly on the plasma membrane and in the cell cytoplasm ( Fig. 1) . Figure 1 shows examples of GPR30 immunostaining of breast cancer tissue with negative staining (Fig. 1a) , slightly positive staining (Fig. 1b) , moderately positive (Fig. 1c) , and strongly positive (Fig. 1d ) cytoplasmic immunostaining. However, in 41 of 323 (12.7%) cases, GPR30 was expressed also in the nucleus, as demonstrated in Fig. 1e . One hundred eighty-three of the 323 (56.7%) paraffinembedded breast cancer specimens available for evaluation of GPR30 expression were classified as positive. All of the surrounding non-tumor mammary tissues included in the tissue specimens were GPR30-positive.
EGFR expression was evaluated in 292 cases. EGFR overexpression was observed in 46 of 292 (15.8%) cases investigated (Table 1) . EGFR expression correlated with GPR30 expression (P = 0.024, Table 2 ) and histological grading (P = 0.009), but did not correlate with HER-2 overexpression (P = 0.447, data not shown). EGFR overexpression was inversely correlated to the ER and PR status (data not shown). Moreover, EGFR status was a poor predictor for DFS and OS in the whole cohort of patients (data not shown).
GPR30 protein expression and tumor characteristics
The results of GPR30 immunohistochemistry were compared with the prognostic parameters age, menopausal status, tumor size, metastases, nodal status, ER, PR, HER-2, and EGFR (Table 2 ). GPR30 immunostaining correlated significantly with HER-2 expression (P = 0.021), EGFR expression (P = 0.024) and lymph node status (0.047). About 70% of the tumors overexpressing HER-2 and EGFR demonstrated moderate or strong GPR30 expression (Table 2) . Similarly, the GPR30-expression was higher in PR positive breast specimens, but without reaching a significant level. GPR30 expression was more often detected in cases of lymph node-negative tumors. There was no correlation between the expression of GPR30 and other tumor characteristics (Table 2 ).
GPR30 and survival
During the follow-up time (51 months median follow-up, range 1-134 months), there were 118 (36.5%) breast cancer relapses, 93 (78.8%) of which occurred under endocrine therapy. There was no significant difference in OS between GPR30-positive and -negative patients (data not shown). However, among all cases, the GPR30 positivity was associated with a significantly decreased RFS (Fig. 2a ,
Patients with GPR30 positive tumors receiving tamoxifen with or without chemotherapy, had poorer RFS than GPR30-negative patients. The 5-year RFS was 70.7% for GPR30-negative patients and 59.6% for GPR30-positive patients (P = 0.030). Univariate analysis revealed that GPR30 expression was a prognostic factor for poor DFS (HR, 1.533; 95% CI, 1.051-2.235; P = 0.026) ( Table 3) . After adjustment for menopausal status, tumor size, lymph node status, tumor grading, HER-2 status, EGFR status, ER status, and PR status, multivariate analysis rendered GPR30 as an independent, unfavorable prognostic factor (HR, 1.768; 95% CI, 1.156-2.703; P = 0.009) ( Table 3) . Among the patients who did not receive tamoxifen as adjuvant therapy, GPR30 seemed to be a favorable factor of RFS (5-year RFS: 66.7 vs. 74.2% for negative and positive cases, respectively) (Fig. 2b) . For patients who did not received tamoxifen, GPR30 negativity was associated with poor RFS. However, this association was not significant (P = 0.204).
Kaplan-Meier survival analysis was subsequently done for GPR30-positive patients in relation to the tamoxifen treatment (Fig. 2c) . The first group consisted of GPR30-positive patients who received only tamoxifen, the second group of GPR30-positive patients treated with aromatase inhibitors or tamoxifen followed by an aromatase inhibitor. Tamoxifen treatment was associated with a significantly poorer RFS compared to the patients who received aromatase inhibitors (P = 0.001; Fig. 2c ). The 5-year RFS 50.4% in patients receiving tamoxifen and 74.2% in patients receiving aromatase inhibitors or tamoxifen followed by an aromatase inhibitor, respectively (P = 0.002). This finding shows that GPR30 expression is associated with poor RFS only in patients treated with tamoxifen.
To verify this observation, the influence of GPR30 on tamoxifen resistance was tested in a second cohort of 103 patients, who received only tamoxifen as adjuvant therapy. GPR30 expression was significantly associated with poorer RFS (Fig. 2d) with a 5-year RFS 58.5 vs. 86.8% for GPR30-positive and GPR30-negative patients, respectively (P = 0.002). Multivariate analysis revealed that GPR30 expression remains an independent unfavorable factor regarding RFS (HR, 4.440; 95% CI, 1.408-13.997, P = 0.011) after adjustment for menopausal status, tumor size, lymph node status, tumor grading, PR status, HER-2 status, and EGFR status (Table 4) . These findings suggested again, that GPR30 is associated with poor RFS in patients treated with tamoxifen.
Change in GPR30 expression between PT and corresponding recurrent tissue
In vitro we have recently found that GPR30 cell surface expression is increased after continuous tamoxifen treatment [4] . To verify these results in vivo we compared the GPR30 expression score between recurrent tissues and their corresponding PTs. Forty-six patients with recurrent breast cancer were investigated. The GPR30 score was obtained in 33 of them. The sites of recurrence included 22 locoregional and 11 distant metastatic lesions. In these lesions, GPR30 expression was evaluated using the above described score and was compared with GPR30 expression in the primary tumor (PT). Twenty-one of these patients had been treated with tamoxifen, 7 with aromatase inhibitor and 5 had received chemotherapy only. GPR30 expression in PTs was determined before the adjuvant therapy. Representative examples of GPR30 expression in PTs and corresponding metastases are shown in Fig. 1i -l. In 12 tumors having recurred during treatment with aromatase inhibitor and/or chemotherapy (Fig. 3a) , GPR30 expression was increased in 8 (66.7%) cases, decreased in The log rank test was used to calculate the P value 1 (8.3%) case and it remained unchanged in 3 (25%) cases (Z value, -1.658; P = 0.114). The mean IHC score in this group of patients was 2.67 in PTs and 4.42 in the recurrent lesions (P = 0.087, Fig. 3b ). However, in 21 tumors treated with tamoxifen, a significant increase in the GPR30 expression score was observed (Z value, -3.212; P = 0.001). Thus, the IHC score had increased in 16 of 21 (76.2%), was unchanged in 2 of 21 (9.5%), and decreased in only 3 of 21 (14.3%) (Fig. 3c) . The mean IHC score for GPR30 was 3.57 and 6.33 in PTs and the recurrent lesions, respectively (P = 0.001, Fig. 3d ).
Discussion
In this study, we investigated the expression of GPR30 in breast cancer and compared it with the RFS and OS in a cohort of 323 patients with invasive breast cancer. This study provides new insights into the mechanisms of acquired tamoxifen resistance and the pivotal role of GPR30. GPR30-positive staining was observed in 183 of 323 (56.7%) invasive breast cancers. In these series, GPR30 expression was associated with poorer RFS but not with OS. Interestingly, GPR30 was associated with a poorer RFS only in patients treated with tamoxifen in the adjuvant setting. In contrast, in a group of patients not having received tamoxifen after operation, GPR30 expression seemed to be even a favorable factor regarding RFS. However, this effect did not reach a significant level. These findings support our recent in vitro results, since GPR30 was associated with an increased resistance of MCF-7 breast cancer cells to tamoxifen [4] . Thus, GPR30 expression is associated with an increased risk of development of tamoxifen resistance.
In this study, we observed a significant correlation between GPR30 and HER-2 and EGFR, two members of a family of four structurally related tyrosine kinase receptors. Amplification of HER-2 and EGFR is one of the most common genetic alterations associated with breast cancer progression. About 70% of the HER-2-and EGFR-positive tumors scored positive for GPR30, revealing a highly significant correlation between GPR30 and both receptors (P = 0.021 and 0.024, respectively). It is in agreement with a very recent investigation of two independent research groups who found that GPR30 significantly correlates with HER-2 expression in breast cancer patients [18, 19] . A correlation between GPR30 and EGFR expression has been reported for endometrial cancer patients [20] . This correlation may be of pivotal impact for tumor cells, since GPR30 can activate EGFR and make the tumor growth independent of ER [21] . Moreover, GPR30 expression is up-regulated in estrogen receptor-negative and estrogen receptor-positive cells by epidermal growth factor [22, 23] and could be a good explanation of our finding that GPR30 expression correlates significantly with EGFR expression. In this context, the EGF-induced GPR30 up-regulation can be a milestone in GPR30-induced tamoxifen resistance.
The role of cross-talk between ER and growth factor receptors causing endocrine therapy resistance in breast cancer cells is well established [12] . An amplification and overexpression of HER-2 gene and increased protein expression occurs in about 12-25% of the human breast cancers [24] [25] [26] . However, the role of EGFR and HER-2 in the development of tamoxifen resistance in vivo is controversial. This association was very recently confirmed in large clinical trials [27] [28] [29] , whereas in other studies, there was no significant correlation [30, 31] . Multivariate analysis demonstrated that GPR30, HER-2, and EGFR are independent unfavorable predictors of RFS under tamoxifen therapy. GPR30 possibly supports the growth of tumors resistant towards tamoxifen by cross-talk with growth factor receptor signaling pathways, which has been observed in vitro [4] , and will make the tumor growth independent of ER signaling [12] . Since tamoxifen acts as an agonist for GPR30 and leads to stimulation of cell proliferation and growth in many cell culture models [7] [8] [9] [10] [11] the growth of GPR30-positive breast cancer may be rather stimulated than inhibited by tamoxifen. The GPR30/ growth factor receptor cross-talk is followed by phosphorylation of MAPK and Akt [4, 7] . Thus, MAPK and Akt can further stimulate transcription of different genes (even ER), leading to cell growth proliferation. Then, again, the phosphorylated ER can further up-regulate GPR30, establishing a vicious circle [4] . Blocking of GPR30/EGFR signaling is a potential target to circumvent the tamoxifen resistance in breast cancer cells.
Prolonged tamoxifen treatment leads to an increased cell surface expression of GPR30 [4] and also to clonal selection of GPR30-positive tumor cells. We found that GPR30 expression is significantly increased in tamoxifen resistant tumor tissues. In contrast, GPR30 expression was not changed between the primary and recurrent tissue if aromatase inhibitor or chemotherapy was used. Since aromatase inhibitors and chemotherapy both reduce the amount of endogenous estrogen without altering GPR30 expression, we can assume that estrogen does not interfere with GPR30, while tamoxifen does. GPR30 expression may change under tamoxifen therapy. Moreover, GPR30-positive patients treated with aromatase inhibitors or tamoxifen followed by aromatase inhibitor demonstrated a longer RFS as compared with the GPR30-positive patients treated with tamoxifen alone. Therefore, GPR30-positivity might define a group of (postmenopausal) patients who benefit more from estrogen deprivation, in terms of aromatase inhibitor therapy, than from tamoxifen. The primary favorable effect of GPR30 expression on RFS in patients, who did not received tamoxifen, could be good explained by very recent results by Ariazi et al. who have find that GPR30 agonist inhibits proliferation of breast cancer cells [32] . In this study, we did not observe a correlation between GPR30 and PR and ER, which is in contrast to other recent studies [18, 19, 33] . The authors have found a significant correlation between GPR30 and ER and PR. Indeed, in our population, the GPR30 immunostaining observed was stronger in ER-and PR-positive tumors, but this correlation did not reach significant levels. This supports the hypothesis that GPR30 and ER signaling are different and independent as already described in some cellular systems (for review [34] ). The fact that 45 of 91 (49.5%) of ER-negative tumors are GPR30-positive demonstrates again that GPR30 does not depend of ER [5, 6, 34] . GPR30 positivity in ERnegative tumors represents a new potential target for endocrine therapy.
In conclusion, this study indicated that GPR30 expression correlated significantly with EGFR and HER-2 expression, and was predictive for development of tamoxifen resistance. GPR30-positive tumors are less likely to benefit from tamoxifen therapy. Estrogen deprivation or blocking of GPR30/growth factor receptor crosstalk may be an alternative way to prevent development of tamoxifen resistance. A large number of patients treated with tamoxifen have to be further investigated in prospective clinical trials to confirm these findings. 
